Filing summary: Rexahn Pharmaceuticals, Inc. — Form 10-Q for the quarter ended September 30, 2019
Entity note: The request identifies Opus Genetics, Inc., but the supplied filing is for Rexahn Pharmaceuticals, Inc. The summary below reflects the filing; verify that it is the intended company and period.
Business context and reporting period
Rexahn was a clinical-stage oncology biopharmaceutical company with no product sales. This unaudited report covers the three and nine months ended September 30, 2019, with comparisons to the same 2018 periods.
Financial results and liquidity
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating expenses | $2.281 million | $4.684 million | $9.207 million | $15.571 million |
| Operating loss | $2.281 million | $4.684 million | $9.207 million | $15.571 million |
| Net loss | $1.959 million | $5.339 million | $6.767 million | $11.252 million |
| Basic and diluted loss per share | $0.49 | $2.02 | $1.72 | $4.26 |
Gross margin is not meaningful because the company reported no revenue. The filing reports no conventional debt; liabilities included $235,449 in operating lease obligations and $123,872 in warrant liabilities at September 30, 2019. Total liabilities were $3.226 million.
At quarter-end, cash and cash equivalents were $7.932 million and marketable securities were $5.982 million, or approximately $13.9 million combined. Current assets were $14.636 million and current liabilities were $3.001 million. Management said available cash, cash equivalents and marketable securities were expected to fund current activities for at least 12 months from issuance of the financial statements, while noting strategic transactions could materially change resource needs.
Operating cash use was $8.565 million for the first nine months of 2019, versus $14.218 million in 2018. Investing activities provided $0.099 million; financing activities provided $7.654 million, primarily from the January 2019 offering. Cash declined by $0.812 million over the period.
Changes versus prior comparable periods
- Q3 operating expenses fell 51% year over year; nine-month expenses fell 41%. General and administrative expenses declined 36% for Q3 and 19% for nine months, mainly due to streamlined operations and lower personnel and operating costs.
- Research and development expenses declined 61% for Q3 and 52% for nine months, reflecting completed trial enrollment, lower manufacturing costs, prior headcount reductions and discontinued preclinical work.
- Net loss narrowed in both periods. Results included noncash gains from revaluing liability-classified warrants: $0.243 million in Q3 2019 and $2.184 million for nine months, compared with a Q3 2018 loss of $0.710 million and a nine-month 2018 gain of $3.752 million. These gains are not operating cash inflows.
- The January 2019 public offering raised approximately $8.6 million gross; the company issued 895,834 shares and warrants for 895,886 shares. A 1-for-12 reverse stock split took effect in April 2019; share and per-share figures were retroactively adjusted.
Outlook, management commentary and risks
- In September 2019, Rexahn began evaluating strategic alternatives, including a sale, merger, business combination, asset sale or licensing transaction, and engaged Oppenheimer as financial adviser. It reduced its workforce to five employees. Management cautioned that there was no assurance of a transaction or increased shareholder value; the filing says the board could consider dissolution and liquidation if no transaction is completed.
- RX-3117’s Phase 2a combination trial with Abraxane reached target enrollment in February 2019. As of July 24, preliminary, unaudited results showed a 23% overall response rate among 40 patients with at least one on-treatment scan and median progression-free survival of approximately 5.4 months. Complete data was expected in 2020. No additional metastatic pancreatic cancer trials were then planned; other development options were under review.
- RX-5902 development strategy was under evaluation; the contemplated Phase 2 combination study with KEYTRUDA might not proceed. Haichang was developing RX-0301 and expected to file an investigational new drug application in 2020.
- Under the BioSense RX-3117 agreement, $1.5 million of the $3.0 million upfront payment had been received; the remaining $1.5 million was overdue at September 30, 2019. No revenue was recognized because the performance obligations had not been satisfied. Potential development and regulatory milestones total up to $126 million, plus sales milestones and royalties, but are contingent and were excluded from recognized revenue.
- Management expected R&D spending to decline through the remainder of 2019 and into 2020. Additional capital could be needed to continue drug development, depending on strategic-alternative outcomes. Risks include clinical and regulatory uncertainty, reliance on third parties, Nasdaq continued-listing requirements, and the possibility that strategic review distracts operations or does not result in a transaction.
- Other disclosed commitments include an estimated $2.420 million to complete vendor service agreements, generally terminable with notice, and a $1 million KRICT milestone payable only after marketing approval of a qualifying product. The filing also describes potential payments to Next BT tied to future RX-0201 sales or licensing revenue.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Rexahn Pharmaceuticals, Inc., not Opus Genetics, Inc.
- Check subsequent disclosures on the strategic-alternatives process, any transaction or liquidation decision, and the company’s current operating status.
- Verify whether BioSense paid the overdue $1.5 million and whether the license or material-transfer performance obligations were later fulfilled.
- Review complete RX-3117 trial results and subsequent development decisions for RX-3117, RX-5902 and RX-0301.
- Assess cash runway against actual operating burn, contractual commitments, and any financing or strategic transaction after September 30, 2019.